Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2

Inclusion Criteria Concurrent Medication: Allowed: Zidovudine (AZT). Necessary topical agents such as nystatin, clotrimazole, and acyclovir. Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis. Oral antibiotics for PCP prophylaxis if hematologically stable for = or > 30 days prior to study entry. Necessary systemic agents for the treatment of other chronic disorders, such as diabetes or asthma. Patients must have: HIV-1 seropositivity. Asymptomatic. No opportunistic infection for 8 weeks prior to study entry. Been on azidothymidine (AZT) (= or > 500 mg/day) for at least 8 weeks prior to beginning interleukin-2 (IL-2), with stable CD4 cell counts. Prior Medication: Allowed: Zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Active, life-threatening opportunistic infection (OI) with bacterial, viral, fungal, or protozoan pathogens. Fever = or > 101 F. within 10 days prior to study entry. Significant central nervous system (CNS) disease including AIDS dementia, psychiatric disability, or seizure disorder. Significant cardiac disease (New York Heart Association Stage III or IV). Significant pulmonary disease (Forced Expiratory Volume < 75 percent. Weight loss = or > 10 percent within last 3 months. Concurrent Medication: Excluded: Systemic therapy for opportunistic infection (OI). Patients with the following are excluded: Presence of antibody to interleukin-2 (IL-2). Diseases or symptoms listed in Exclusion Co-Existing Conditions. Prior Medication: Excluded within 12 weeks prior to study entry: Other immunomodulators. Corticosteroids. Other experimental therapy. Anti-neoplastic chemotherapy. Active drug or alcohol abuse.